TitleGene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer.
Publication TypeJournal Article
Year of Publication2006
AuthorsSørlie, T, Perou, CM, Fan, C, Geisler, S, Aas, T, Nobel, A, Anker, G, Akslen, LA, Botstein, D, Børresen-Dale, A-L, Lønning, PEystein
JournalMol Cancer Ther
Date Published2006 Nov
KeywordsAdult, Aged, Aged, 80 and over, Antibiotics, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Carcinoma, Ductal, Breast, Doxorubicin, Female, Fluorouracil, Gene Expression Profiling, Humans, Middle Aged, Mitomycin, Neoadjuvant Therapy, Oligonucleotide Array Sequence Analysis, Prospective Studies, Treatment Outcome, Tumor Suppressor Protein p53

Neoadjuvant treatment offers an opportunity to correlate molecular variables to treatment response and to explore mechanisms of drug resistance in vivo. Here, we present a statistical analysis of large-scale gene expression patterns and their relationship to response following neoadjuvant chemotherapy in locally advanced breast cancers. We analyzed cDNA expression data from 81 tumors from two patient series, one treated with doxorubicin alone (51) and the other treated with 5-fluorouracil and mitomycin (30), and both were previously studied for correlations between TP53 status and response to therapy. We observed a low frequency of progressive disease within the luminal A subtype from both series (2 of 36 versus 13 of 45 patients; P = 0.0089) and a high frequency of progressive disease among patients with luminal B type tumors treated with doxorubicin (5 of 8 patients; P = 0.0078); however, aside from these two observations, no other consistent associations between response to chemotherapy and tumor subtype were observed. These specific associations could possibly be explained by covariance with TP53 mutation status, which also correlated with tumor subtype. Using supervised analysis, we could not uncover a gene profile that could reliably (>70% accuracy and specificity) predict response to either treatment regimen.

Alternate JournalMol. Cancer Ther.